Brind.

MarketBeat Provides Analyst Ratings and Financial Tracking for Recursion Pharmaceuticals

2 reports, 1 independent Updated Sep 22
Gone quiet
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

MarketBeat has begun providing analyst ratings for Recursion Pharmaceuticals. The ratings are part of a larger comparison between Recursion Pharmaceuticals and Bicycle Therapeutics, two healthcare companies. The comparison covers institutional ownership, insider ownership, volatility, profitability, and valuation.

From dailypolitical.com

Why it matters

Some supportBrind's analysis of the reports

The reports detail that 89.1% of Recursion Pharmaceuticals shares are held by institutional investors, while 6.7% are held by company insiders. The comparison also notes that Recursion Pharmaceuticals has a beta of 1.07, indicating its stock price is 7% more volatile than the S&P 500.

From dailypolitical.com

Who's involved

  • MarketBeatAmerican personal finance blog providing analyst ratings and market data.
  • Recursion (United States)Company whose financial performance and analyst ratings are being tracked.

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
1 more outlet ran the same wire story